Skip to main content

Table 2 Demographic and visual acuity results according to the Snellen equivalent of enrolled subjects

From: Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study

No./age (years)/sex/eye

Baseline BCVA

Best follow-up BCVA

6-month BCVA

1/44/male/OD

LP

LP

LP

2/57/male/OD

LP

LP

LP

3/42/female/OS

LP

LP

LP

4/34/male/OS

20/20000

20/20000

20/20000

5/34/male/OS

20/2000

20/400

20/2000

6/30/female/OD

20/20000

20/2000

20/2000

7/29/male/OS

20/20000

20/2000

20/2000

8/47/male/OS

LP

LP

LP

9/26/male/OD

20/20000

20/400

20/400

10/46/female/OS

LP

LP

LP

11/32/male/OS

20/20000

20/20000

20/20000

  1. BCVA best corrected visual acuity, LP light perception, RE Right eye, LE Left eye